** Shares of vaccine maker Moderna fall 13.6% to $36.20 premarket
** Co cut its 2025 sales forecast by $1 billion, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines
** Co expects $1.5 bln to $2.5 bln in annual revenue, lower than its prior forecast of $2.5 bln to $3.5 bln
** Analysts on average were expecting annual revenue of $2.95 bln, according to data from LSEG
** Co expects to end 2025 with cash and investments of about $6 billion
** Up to last close, stock had fallen 61.4% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.